Correction to: Nicotinamide riboside for peripheral artery disease: the NICE randomized clinical trial (Nature Communications, (2024), 15, 1, (5046), 10.1038/s41467-024-49092-5)

Mary M. McDermott*, Christopher R. Martens, Kathryn J. Domanchuk, Dongxue Zhang, Clara B. Peek, Michael H. Criqui, Luigi Ferrucci, Philip Greenland, Jack M. Guralnik, Karen J. Ho, Melina R. Kibbe, Kate Kosmac, Donald Lloyd-Jones, Charlotte A. Peterson, Robert Sufit, Lu Tian, Stephanie Wohlgemuth, Lihui Zhao, Pei Zhu, Christiaan Leeuwenburgh

*Corresponding author for this work

Research output: Contribution to journalComment/debatepeer-review

Abstract

Correction to: Nature Communicationshttps://doi.org/10.1038/s41467-024-49092-5, published online 13 June 2024 The abstract for this article was inadvertently truncated after the text ‘…A larger clinical trial to confirm these findings is needed.’; the following text was missing ‘Clinical Trials.gov registration: NCT03743636’. The original article has been updated.

Original languageEnglish (US)
Article number6890
JournalNature communications
Volume15
Issue number1
DOIs
StatePublished - Dec 2024

ASJC Scopus subject areas

  • General Chemistry
  • General Biochemistry, Genetics and Molecular Biology
  • General Physics and Astronomy

Fingerprint

Dive into the research topics of 'Correction to: Nicotinamide riboside for peripheral artery disease: the NICE randomized clinical trial (Nature Communications, (2024), 15, 1, (5046), 10.1038/s41467-024-49092-5)'. Together they form a unique fingerprint.

Cite this